Midterm Outcomes of Combination Therapy With Immune Checkpoint Inhibitors and VEGFR-TKIs in Real-World Patients With Advanced Renal Cell Carcinoma - PubMed
5 hours ago
- #immunotherapy
- #renal cell carcinoma
- #targeted therapy
- Combination therapy with immune checkpoint inhibitors and VEGFR-TKIs (IO-TKI) shows feasible effectiveness and manageable safety in advanced renal cell carcinoma (RCC) patients.
- Median progression-free survival (PFS) was 19.9 months, and overall survival (OS) was 46.7 months in a study of 68 patients.
- Clear-cell RCC patients had better outcomes than non-clear-cell RCC patients, with median PFS of 23.0 vs. 13.8 months and OS not reached vs. 37.4 months.
- Grade 3 adverse events occurred in 65% of patients, with treatment discontinuation required in 21% for both drugs and 31% for one drug.
- High-dose glucocorticoids were needed in 15% of patients, indicating significant but manageable toxicity.
- The study highlights the need for more effective treatments for non-clear-cell RCC patients.